Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Boots Vitamin E 400unit capsules
0906050P0BYADAF
|
Boots Vitamin E | Vitamin E | Nutrition and Blood | No data available |
|
Boots Warming Pain Relief spray
1003020N0BRAAA0
|
Boots Warming Pain Relief | Methyl salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Boots Witch Hazel gel
1311060H0BEAAAB
|
Boots Witch Hazel | Hamamelis | Skin | No data available |
|
Borax powder
190900000AAAHAH
|
Generic compound preparation BNF 1909000 | Other disinfectant,preservative and sterilising preparations | Other Drugs and Preparations | No data available |
|
Boric acid powder
190900000AAAJAJ
|
Generic compound preparation BNF 1909000 | Other disinfectant,preservative and sterilising preparations | Other Drugs and Preparations | No data available |
|
Bortezomib 3.5mg powder for solution for injection vials
0801050ACAAAAAA
|
Bortezomib | Bortezomib | Malignant Disease and Immunosuppression | No data available |
|
Bosentan 62.5mg tablets
0205010U0AAAAAA
|
Bosentan | Bosentan | Cardiovascular System | No data available |
|
Bosulif 100mg tablets
0801050BLBBAAAA
|
Bosulif | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosulif 400mg tablets
0801050BLBBACAC
|
Bosulif | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosulif 500mg tablets
0801050BLBBABAB
|
Bosulif | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosutinib 100mg tablets
0801050BLAAAAAA
|
Bosutinib | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosutinib 400mg tablets
0801050BLAAACAC
|
Bosutinib | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosutinib 500mg tablets
0801050BLAAABAB
|
Bosutinib | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Botanics Lavender pure essential oil
190605000BBNRA0
|
Proprietary compound preparation BNF 1906050 | Other oil preparations | Other Drugs and Preparations | No data available |
|
Botanics Tea Tree pure essential oil
190605000BBNTA0
|
Proprietary compound preparation BNF 1906050 | Other oil preparations | Other Drugs and Preparations | No data available |
|
Botulinum toxin type A 125unit inj vials
0409030B0AAAFAF
|
Botulinum toxin type A | Botulinum toxin type A | Central Nervous System | No data available |
|
Botulinum toxin type A 200unit inj vials
0409030B0AAAGAG
|
Botulinum toxin type A | Botulinum toxin type A | Central Nervous System | No data available |
|
Botulinum toxin type A 300unit inj vials
0409030B0AAAHAH
|
Botulinum toxin type A | Botulinum toxin type A | Central Nervous System | No data available |
|
Botulinum toxin type A 500unit inj vials
0409030B0AAAAAA
|
Botulinum toxin type A | Botulinum toxin type A | Central Nervous System | No data available |
|
Botulinum toxin type B 10,000units/2ml inj vials
0409030A0AAACAC
|
Botulinum toxin type B | Botulinum toxin type B | Central Nervous System | No data available |
|
Botulinum toxin type B 2,500units/0.5ml inj vials
0409030A0AAAAAA
|
Botulinum toxin type B | Botulinum toxin type B | Central Nervous System | No data available |
|
Botulinum toxin type B 5,000units/1ml inj vials
0409030A0AAABAB
|
Botulinum toxin type B | Botulinum toxin type B | Central Nervous System | No data available |
|
Brabio 20mg/1ml solution for injection pre-filled syringes
0802040U0BCAAAB
|
Brabio | Glatiramer acetate | Malignant Disease and Immunosuppression | No data available |
|
Bradosol Plus lozenges
1203030M0BHABAM
|
Bradosol Plus | Lidocaine hydrochloride | Ear, Nose and Oropharynx | No data available |
|
Bradosol Sugar Free Cherry Menthol 500microgram lozenges
1203030T0BBAAAA
|
Bradosol (Lozenges) | Benzalkonium chloride | Ear, Nose and Oropharynx | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.